1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Interview: C4XD Chief Sees Indivior Pact As First Of Many

 
• By Kevin Grogan

The deal for an oral orexin-1 receptor antagonist which aims to treat addiction by targeting the craving process validates C4XD's strategy of out-licensing preclinical programs. CEO Clive Dix told Scrip more agreements will follow as the firm "is not a one-trick pony."

Steps
Solid first step: C4XD signs its first major deal • Source: Shutterstock

Shares in C4X Discovery Holdings PLC have rocketed after the company licensed a potential best-in-class addiction candidate to fellow UK firm Indivior PLC in a deal that could be worth up to $294m.

The pact, for which C4XD is getting $10m up front and a further $284m of potential development, regulatory and commercialization...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

More from Therapy Areas

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.